Skip to content
Hair Pipeline
← Back to the pipeline

BL 3000

An undisclosed Biolab oral candidate at phase 3 in telogen effluvium.

Phase 3OralUndisclosed

No public activity in over 18 months

Developed by
Biolab Sanus Farmacêutica
Current phase
Phase 3

Large confirmatory trials. The last step before filing.

Indications
Telogen effluvium
Last public activity
July 2022
Record confidence
Low

Why it matters

Telogen effluvium — diffuse shedding after illness, childbirth or stress — has no approved drug anywhere, and is the indication most readers of this register describe when they say their hair "suddenly started falling out". A registrational trial aimed at it is rare enough to record even undisclosed.

Development history

  1. Phase 3

    First Phase 3 trial on record: NCT04880889 — BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT04880889Phase 3UNKNOWN

    BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

    Biolab Sanus Farmaceutica · n=326 · January 2023

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources